A5021176687- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Disaster Management and Resilience
- Hepatitis C virus research
- Pneumocystis jirovecii pneumonia detection and treatment
- Disaster Response and Management
- Healthcare Policy and Management
- Misinformation and Its Impacts
- Primary Care and Health Outcomes
- Early Childhood Education and Development
- Patient Satisfaction in Healthcare
- Children's Rights and Participation
- Cardiac Arrhythmias and Treatments
- Vaccine Coverage and Hesitancy
- Cardiomyopathy and Myosin Studies
- Heat shock proteins research
- Cytomegalovirus and herpesvirus research
- Poverty, Education, and Child Welfare
- Education Systems and Policy
- Biochemical and Molecular Research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Resilience and Mental Health
- Plant biochemistry and biosynthesis
Medizinisches Versorgungszentrum Prof. Mathey, Prof. Schofer
2025
University of Minnesota
2023-2024
Minnesota Department of Education
2024
Endress+Hauser (Switzerland)
2023
University of Minnesota System
2022-2023
University of Tennessee Health Science Center
2023
Université Claude Bernard Lyon 1
2022
Universitätsklinikum Gießen und Marburg
2022
Klinik und Poliklinik für Urologie, Kinderurologie und Andrologie
2022
St. Josefs Hospital
2022
Assays for drug resistance testing in human immunodeficiency virus type 1 (HIV-1) infection are now available and clinical studies suggest that viral is correlated with poor virologic response to new therapy. The International AIDS Society-USA sought update prior recommendations provide guidance clinicians regarding indications HIV-1 testing.An 13-member physician panel expertise basic science, research, patient care involving HIV antiretroviral drugs was reconvened the use of testing.The...
Resistance to antiretroviral drugs remains an important limitation successful human immunodeficiency virus type 1 (HIV-1) therapy. testing can improve treatment outcomes for infected individuals. The availability of new from various classes, standardization resistance assays, and the development viral tropism tests necessitate guidelines testing. International AIDS Society-USA convened a panel physicians scientists with expertise in drug-resistant HIV-1, drug management, patient care review...
New information about the benefits and limitations of testing for resistance to human immunodeficiency virus (HIV) type 1 (HIV-1) drugs has emerged. The International AIDS Society-USA convened a panel physicians scientists with expertise in antiretroviral drug management, HIV-1 resistance, patient care provide updated recommendations testing. Published data presentations at scientific conferences, as well strength evidence, were considered. Properly used can improve virological outcome among...
The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside inhibitor or ritonavir-boosted protease is recommended as initial therapy in patients human immunodeficiency virus type 1 (HIV-1) infection, but which NRTI has greater efficacy and safety not known.In randomized, blinded equivalence study involving 1858 eligible patients, we compared four once-daily antiretroviral regimens for HIV-1 infection: abacavir-lamivudine tenofovir disoproxil...
A standardized antiviral drug susceptibility assay for clinical human immunodeficiency virus type 1 (HIV-1) isolates has been developed use in trials. The protocol is a two-step procedure that first involves cocultivation of patient infected peripheral blood mononuclear cells (PBMC) with seronegative phytohemagglutinin-stimulated donor PBMC to obtain an HIV-1 stock. stock titrated viral infectivity (50% tissue culture infective dose) by serial fourfold dilutions PBMC. inoculum 1,000 50%...
Data from 1330 human immunodeficiency virus type 1 (HIV-1)-infected patients enrolled in seven antiretroviral treatment trials were analyzed to characterize the clinical benefit of treatment-mediated reductions plasma HIV-1 RNA levels. The risk a new AIDS-defining event or death was reduced proportionally magnitude reduction level during first 6 months therapy. Pretherapy levels prognostic independently ontherapy In addition, associated with any given did not vary by pretherapy level. Having...
It is unclear whether therapy for human immunodeficiency virus type 1 (HIV-1) should be initiated with a four-drug or two sequential three-drug regimens.
Background. The clinical relevance of detecting minority drug-resistant human immunodeficiency virus type 1 (HIV-1) variants is uncertain. Methods. To determine the effect pre-existing nonnucleoside reverse-transcriptase inhibitor (NNRTI)-resistant on risk virologic failure, we reanalyzed a case-cohort substudy efavirenz recipients in AIDS Clinical Trials Group protocol A5095. Minority K103N or Y181C populations were determined by allele-specific polymerase chain reaction subjects without...
Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in subjects coinfected with HIV. Tenofovir disoproxil fumarate (TDF) adefovir dipivoxil (ADV) are licensed for the treatment HIV-1 HBV infection, respectively, but both have vivo vitro activity against HBV. This study evaluated anti-HBV TDF compared to ADV HIV/HBV-coinfected subjects. ACTG A5127 was a prospective randomized, double-blind, placebo-controlled trial daily 10 mg versus 300 HIV coinfection...
A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on response efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort efavirenz-treated subjects plus unselected who experienced virologic failure. Of 220 cohort, 57 (26%) had prevalence NNRTI resistance 5%. risk failure for with higher than that without such (hazard ratio 2.27 [95%...